Novartis (0K9E) Share Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0K9E Analyst Ratings

Hold

2 Buy

2 Hold

1 Sell

Based on 5 analysts giving stock ratings to

Novartis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0K9E Stock 12 Month Forecast

Average Price Target

$159.00

▲(2.43% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Novartis in the last 3 months. The average price target is $159.00 with a high forecast of $180.00 and a low forecast of $139.00. The average price target represents a 2.43% change from the last price of $155.23.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"113":"$113","130":"$130","147":"$147","164":"$164","181":"$181"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":159,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$159.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":139,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$139.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[113,130,147,164,181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,156.479,158.2883076923077,160.0976153846154,161.90692307692308,163.71623076923078,165.52553846153847,167.33484615384617,169.14415384615384,170.95346153846154,172.76276923076924,174.57207692307693,176.3813846153846,178.1906923076923,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,156.479,156.6729230769231,156.86684615384615,157.06076923076924,157.25469230769232,157.44861538461538,157.64253846153846,157.83646153846155,158.03038461538463,158.2243076923077,158.41823076923077,158.61215384615386,158.80607692307692,{"y":159,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,156.479,155.13446153846155,153.7899230769231,152.44538461538463,151.10084615384616,149.7563076923077,148.41176923076924,147.06723076923078,145.7226923076923,144.37815384615385,143.0336153846154,141.68907692307693,140.34453846153846,{"y":139,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":114.551,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":124.183,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":127.998,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":121.301,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":127.47,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":135.699,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":147.126,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":163.34,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":155.039,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.78,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.68,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.636,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.479,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$180.00

Average Price Target$159.00

Lowest Price Target$139.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Steve Scala

TD Cowen

$180

Hold

15.96%

Upside

Reiterated

07/27/26

Novartis: Balanced Upside Potential and Execution Risks Lead Analyst to Maintain Hold Rating Ahead of Key Phase III Readouts

Kerry Holford

Berenberg Bank

$141→$147

Hold

-5.30%

Downside

Reiterated

07/27/26

Berenberg Bank Remains a Hold on Novartis (NVS)

Jasper Hellweg

Argus Research

$170

Buy

9.51%

Upside

Reiterated

07/24/26

Analysts Offer Insights on Healthcare Companies: Novartis (NYSE: NVS) and NeoGenomics (NASDAQ: NEO)

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

$140→$139

Sell

-10.46%

Downside

Reiterated

07/22/26

Novartis (NVS) Receives a Sell from Goldman Sachs

Sachin Jain

Bank of America Securities

―

Buy

―

Reiterated

07/21/26

Analysts' Top Healthcare Picks: Novartis (NVS), 4D Molecular Therapeutics (FDMT)

Thibault Boutherin

Morgan Stanley

$143→$170

Buy

9.51%

Upside

Reiterated

03/26/26

Morgan Stanley Sticks to Its Buy Rating for Novartis (NVS)

Justin Smith

Bernstein

―

Hold

―

Initiated

03/19/26

Novartis (NVS) Receives a New Rating from Bernstein

Emily Field

Barclays

―

Hold

―

Upgraded

01/06/26

Novartis upgraded to Equal Weight from Underweight at BarclaysNovartis upgraded to Equal Weight from Underweight at Barclays

Rajesh Kumar

HSBC

$106→$112

Sell

-27.85%

Downside

Reiterated

12/10/25

Novartis price target raised to $112 from $106 at HSBCNovartis price target raised to $112 from $106 at HSBC

Richard Vosser

J.P. Morgan

―

Hold

―

Reiterated

11/20/25

J.P. Morgan Sticks to Its Hold Rating for Novartis (NVS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Steve Scala

TD Cowen

$180

Hold

15.96%

Upside

Reiterated

07/27/26

Novartis: Balanced Upside Potential and Execution Risks Lead Analyst to Maintain Hold Rating Ahead of Key Phase III Readouts

Kerry Holford

Berenberg Bank

$141→$147

Hold

-5.30%

Downside

Reiterated

07/27/26

Berenberg Bank Remains a Hold on Novartis (NVS)

Jasper Hellweg

Argus Research

$170

Buy

9.51%

Upside

Reiterated

07/24/26

Analysts Offer Insights on Healthcare Companies: Novartis (NYSE: NVS) and NeoGenomics (NASDAQ: NEO)

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

$140→$139

Sell

-10.46%

Downside

Reiterated

07/22/26

Novartis (NVS) Receives a Sell from Goldman Sachs

Sachin Jain

Bank of America Securities

―

Buy

―

Reiterated

07/21/26

Analysts' Top Healthcare Picks: Novartis (NVS), 4D Molecular Therapeutics (FDMT)

Thibault Boutherin

Morgan Stanley

$143→$170

Buy

9.51%

Upside

Reiterated

03/26/26

Morgan Stanley Sticks to Its Buy Rating for Novartis (NVS)

Justin Smith

Bernstein

―

Hold

―

Initiated

03/19/26

Novartis (NVS) Receives a New Rating from Bernstein

Emily Field

Barclays

―

Hold

―

Upgraded

01/06/26

Novartis upgraded to Equal Weight from Underweight at BarclaysNovartis upgraded to Equal Weight from Underweight at Barclays

Rajesh Kumar

HSBC

$106→$112

Sell

-27.85%

Downside

Reiterated

12/10/25

Novartis price target raised to $112 from $106 at HSBCNovartis price target raised to $112 from $106 at HSBC

Richard Vosser

J.P. Morgan

―

Hold

―

Reiterated

11/20/25

J.P. Morgan Sticks to Its Hold Rating for Novartis (NVS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novartis

3 Months

Thibault BoutherinMorgan Stanley

Success Rate

2/2 ratings generated profit

Average Return

+13.25%

Copying Thibault Boutherin's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +13.25% per trade.

1 Year

Thibault BoutherinMorgan Stanley

Success Rate

2/2 ratings generated profit

Average Return

+12.65%

Copying Thibault Boutherin's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +12.65% per trade.

2 Years

Thibault BoutherinMorgan Stanley

Success Rate

2/2 ratings generated profit

Average Return

+12.65%

Copying Thibault Boutherin's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +12.65% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0K9E Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0K9E has received 4 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. 0K9E average Analyst price target in the past 3 months is 159.00.

Each month's total comprises the sum of three months' worth of ratings.

0K9E Financial Forecast

0K9E Earnings Forecast

Next quarter’s earnings estimate for 0K9E is $2.21 with a range of $2.06 to $2.33. The previous quarter’s EPS was $2.41. 0K9E beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0K9E has Performed in-line its overall industry.

0K9E Sales Forecast

Next quarter’s sales forecast for 0K9E is $14.59B with a range of $14.33B to $14.86B. The previous quarter’s sales results were $14.42B. 0K9E beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0K9E has Performed in-line its overall industry.

0K9E Stock Forecast FAQ

What is GB:0K9E’s average 12-month price target, according to analysts?

Based on analyst ratings, Novartis Ag’s 12-month average price target is 159.00.

What is GB:0K9E’s upside potential, based on the analysts’ average price target?

Novartis Ag has 2.43% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novartis Ag a Buy, Sell or Hold?

Novartis Ag has a consensus rating of Hold, which is based on 2 buy ratings, 2 hold ratings and 1 sell ratings.

What is Novartis Ag’s share price target?

The average share price target for Novartis Ag is 159.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $180.00 ,and the lowest forecast is $139.00. The average share price target represents 2.43% Increase from the current price of $155.23.

What do analysts say about Novartis Ag?

Novartis Ag’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Novartis Ag?

To buy shares of GB:0K9E, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Novartis (0K9E) Share Forecast & Price Target

0K9E Analyst Ratings

0K9E Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novartis

0K9E Analyst Recommendation Trends

0K9E Financial Forecast

0K9E Earnings Forecast

0K9E Sales Forecast

0K9E Stock Forecast FAQ

Detailed List of Analyst Forecasts